QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NKTR

QT25Nektar Therapeutics
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
60.98
+0.06+0.10%
OverviewShort InterestFilings
NKTRQT25Nektar Therapeutics·NASDAQ
OverviewShort InterestFilings
60.98+0.10%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-8.42
Insider Own-
Shs Outstand-
Perf Week2.99%
Market Cap1.19BForward P/E-EPS next Y-11.07Insider Trans-Shs Float-Perf Month-9.77%
Enterprise Value1.20BPEG7.76EPS next Q-2.05Inst Own-Short Float-Perf Quarter-18.52%
Income-124876406.00P/S21.40EPS this Y-7.62%Inst Trans-Short Ratio-Perf Half Y24.04%
Sales55.63MP/B2.62EPS next Y-22.20%ROA-20.71%Short Interest-Perf YTD44.23%
Book/sh-P/C-EPS next 5Y-ROE-87.00%52W High109.01 -44.06%Perf Year598.51%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-17.17%52W Low8.27 637.36%Perf 3Y-
Dividend Est.-EV/EBITDA-9.54Sales past 3/5Y-15.76% -18.50%Gross Margin99.38%Volatility2.60% 3.15%Perf 5Y-
Dividend TTM-EV/Sales21.61EPS Y/Y TTM3.23%Oper. Margin-224.88%ATR (14)3.11Perf 10Y-
Dividend Ex-Date-Quick Ratio10.21Sales Y/Y TTM-42.86%Profit Margin-284.18%RSI (14)39.24Recom2.33
Dividend Gr. 3/5Y-Current Ratio10.21EPS Q/Q44.85%SMA20-0.51%Beta2.40Target Price149.60
Payout0.00%Debt/Eq0.25Sales Q/Q10.00%SMA50-17.59%Rel Volume0.87Prev Close60.92
Employees61LT Debt/Eq1.42EarningsAug 06SMA2000.40%Avg Volume1.05MPrice60.98
IPO DateMay 03, 1994Option/ShortYes / YesEPS/Sales Surpr.-4.60% 0.00%Net Debt/EBITDA-0.09Volume909,495Change0.10%
Analyst Ratings
DateActionAnalystRatingTarget
May-11-26ReiteratedWedbushNeutral$95 → $80
May-08-26ReiteratedPiper SandlerOverweight$105 → $192
Apr-21-26ReiteratedWedbushNeutral$95
Apr-20-26ReiteratedH.C. WainwrightNeutral$165 → $185
Mar-13-26ReiteratedOppenheimerOutperform$115 → $140
Feb-10-26ReiteratedH.C. WainwrightNeutral$135 → $165
Feb-10-26ReiteratedBTIGBuy$151
Jan-26-26ReiteratedPiper SandlerOverweight$105
Dec-16-25ReiteratedH.C. WainwrightNeutral$120 → $135
Dec-16-25ReiteratedOppenheimerOutperform$98 → $115
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue565598
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A0031
Gross Profit565568
Selling, General and Administrative Excl. Other576977
Research and Development123117121
Other Operating Expense00-25
Operating Income-125-131-105
Interest Expense292628
Unusual Expense
———
Non-Operating Income (Expense)27-14
Net Income Before Taxes-159-164-119
Income Taxes000
Consolidated Net Income-159-164-119
Net Income From Continuing Operations-159-164-119
Net Income-159-164-119
EPS (Recurring)-8.42-9.73-8.68
EPS (Basic, Before Extraordinaries)-8.42-9.73-8.68
EPS (Diluted)-8.42-9.73-8.68
EBITDA-126-137-87
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio27.2213.07—
Gross Margin100.00100.0069.39
Operating Margin-223.21-238.18-107.14
Net Margin-283.93-298.18-121.43
Shares Outstanding251714
Market Capitalization1,525719—
Operating Lease Expense
———
Insider Trading Volume
$64.05$59.74$55.42$51.11$46.80● Close Price0.00K214.93K429.85K644.78K859.70KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zalevsky JonathanChief R&D OfficerJun 15 '26Sale60.715,538336,21215,437Jun 17 12:00 AM
Zalevsky JonathanChief R&D OfficerMay 19 '26Sale65.5119913,03620,975May 21 12:00 AM
ROBIN HOWARD WPresident & CEOMay 19 '26Sale65.5144429,08675,045May 21 12:00 AM
Zalevsky JonathanChief R&D OfficerFeb 18 '26Sale73.0018013,14021,174Feb 20 12:00 AM
ROBIN HOWARD WPresident & CEOFeb 18 '26Sale73.0042330,87975,489Feb 20 12:00 AM
Zalevsky JonathanChief R&D OfficerJan 20 '26Sale35.673,867137,93621,354Jan 22 12:00 AM
Wilson Mark AndrewChief Legal OfficerNov 25 '25Sale54.2863034,19621,585Nov 25 12:00 AM
Zalevsky JonathanChief R&D OfficerNov 25 '25Sale54.281,15762,80218,971Nov 25 12:00 AM
ROBIN HOWARD WPresident & CEONov 25 '25Sale54.282,207119,79654,245Nov 25 12:00 AM
ROBIN HOWARD WPresident & CEOSep 09 '25Sale46.696,666311,21449,342Sep 11 12:00 AM
ROBIN HOWARD WPresident & CEOSep 05 '25Sale38.536,666256,85056,008Sep 08 12:00 AM
Zalevsky JonathanChief R&D OfficerSep 04 '25Sale33.521,72157,69217,462Sep 08 12:00 AM
ROBIN HOWARD WPresident & CEOSep 04 '25Sale33.705,166174,10862,674Sep 08 12:00 AM
Zalevsky JonathanChief R&D OfficerSep 02 '25Sale30.1048514,59919,183Sep 04 12:00 AM
ROBIN HOWARD WPresident & CEOSep 02 '25Sale30.161,50045,24067,840Sep 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR